CUSP06 is a CDH6-directed ADC with a differentiated profile and potentially best-in-class activity CUSP06 demonstrated a manageable safety profile, consistent with other TOP1-inhibitor ADCs Promising signs of efficacy were observed in patients with heavily pretreated platinum-resistant...
Hence then, the article about oncusp therapeutics announces encouraging initial phase 1a results from ongoing first in human study evaluating its cdh6 directed antibody drug conjugate cusp06 in platinum refractory resistant ovarian cancer and other advanced solid tumo was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( OnCusp Therapeutics Announces Encouraging Initial Phase 1a Results from Ongoing First-in-Human Study Evaluating its CDH6-Directed Antibody-Drug Conjugate, CUSP06, in Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumo )
Also on site :
- China's First Domestic Anti-CTLA-4 Monoclonal Antibody, Innovent's TABOSUN® (Ipilimumab N01 Injection) Received NMPA Approval
- Goldman Sachs expects layoffs to keep rising—and says investors are punishing the stocks of companies that slash staff
- Prominent Canadian Musician Says Gig Was Cancelled After Google AI Overview Wrongly Branded Him Sex Pest